Health Catalyst, Inc. (HCAT) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $1.12. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of HCAT = $1.38 (+23.2% from the current price, the stock appears undervalued). Analyst consensus target is HCAT = $3 (+167.9% upside).
Valuation: HCAT trades at a trailing Price-to-Earnings (P/E) of -0.4 (S&P 500 average ~25).
Financials: revenue is $311M, +4.1%/yr average growth. Net income is $178M (loss), growing at -33.6%/yr. Net profit margin is -57.2% (negative). Gross margin is 33.5% (-14.7 pp trend).
Balance sheet: total debt is $171M against $246M equity (Debt-to-Equity (D/E) ratio 0.7, moderate). Current ratio is 1.89 (strong liquidity). Debt-to-assets is 34.1%. Total assets: $503M.
Analyst outlook: 12 / 22 analysts rate HCAT as buy (55%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 30/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 29/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
